This study involved a one-time point assessment for GDM at 24 – 28 weeks gestational age, and there was no post-partum follow-up OGTT and SHBG assay of the participants to ascertain the role of the biomarker in the monitoring of GDM as suggested in a similar previous study24. This evidence concerns the gene SHBG and gestational diabetes.